Ocular Therapeutix (OCUL) Cost of Revenue (2013 - 2026)

Ocular Therapeutix has reported Cost of Revenue for 14 years, with the latest figure at $1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cost of Revenue fell 90.61% year-over-year to $1.3 million; the trailing twelve-month figure through Mar 2026 stood at $18.0 million (down 34.44% YoY), and the FY2025 full-year result was $53.9 million, up 858.44% from the prior year.
• Cost of Revenue for Q1 2026 stood at $1.3 million, down from $13.0 million in the prior quarter.
• The five-year high for Cost of Revenue was $36.7 million in Q4 2023, with the low at $1.0 million in Q4 2022.
• Average Cost of Revenue over 5 years is $7.4 million, with a median of $1.9 million recorded in 2025.
• Year-over-year, Cost of Revenue soared 3521.94% in 2023 and tumbled 96.64% in 2024.
• Tracing OCUL's Cost of Revenue over 5 years: stood at $1.0 million in 2022, then soared by 3521.94% to $36.7 million in 2023, then plunged by 96.64% to $1.2 million in 2024, then surged by 953.41% to $13.0 million in 2025, then sank by 89.74% to $1.3 million in 2026.
• The last three Cost of Revenue figures came in at $1.3 million (Q1 2026), $13.0 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.

Peer Comparison